Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rhenium-186 + triamcinolone hexacetonide
- Development stage
- Unknown
- Lead developer
- CISBIO
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intraarticular
01
Overview
Rhenium-186 + triamcinolone hexacetonide is a combination therapy used for radiosynoviorthesis (radiation synovectomy) in rheumatoid arthritis. This combination consists of the radiopharmaceutical rhenium-186 and the corticosteroid triamcinolone hexacetonide. Clinical studies have shown that this combination provides better clinical results and slower progression in radiological destruction compared to either component used alone. The treatment is administered via intra-articular injection into affected joints such as shoulder, elbow, wrist, hip, and ankle joints.
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on rhenium-186 + triamcinolone hexacetonide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rhenium-186 + triamcinolone hexacetonide.